CymaBay Therapeutics (CBAY) Earns Daily News Impact Score of 0.06
Media headlines about CymaBay Therapeutics (NASDAQ:CBAY) have trended somewhat positive on Friday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CymaBay Therapeutics earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.242786797275 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Cymabay Therapeutics, Inc. (CBAY) – Lookout Watch List stock – Wall Street Morning (wallstreetmorning.com)
- Cymabay Therapeutics, Inc. (CBAY) stock uncovered monthly dull performance with sinking progress of -13.83% – Stocks Gallery (stocksgallery.com)
- CymaBay Therapeutics Inc (CBAY) Ichimoku Reading Holds Above the Cloud – Evergreen Caller (evergreencaller.com)
- Securities Analyst Recommendations: Cardinal Health, Inc. (CAH), Cymabay Therapeutics, Inc. (CBAY) – ExpressNewsline (expressnewsline.com)
- Research Analysts Set Expectations for CymaBay Therapeutics Inc.’s Q3 2017 Earnings (CBAY) (americanbankingnews.com)
Shares of CymaBay Therapeutics (NASDAQ CBAY) opened at 6.24 on Friday. The company’s 50-day moving average price is $6.81 and its 200 day moving average price is $4.82. The firm’s market capitalization is $273.04 million. CymaBay Therapeutics has a 12-month low of $1.15 and a 12-month high of $8.29.
CymaBay Therapeutics (NASDAQ:CBAY) last released its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.06. On average, equities research analysts forecast that CymaBay Therapeutics will post ($0.80) EPS for the current fiscal year.
Several analysts recently commented on the company. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $12.00 target price on shares of CymaBay Therapeutics in a report on Tuesday, July 25th. Zacks Investment Research lowered CymaBay Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Oppenheimer Holdings, Inc. raised their target price on CymaBay Therapeutics from $8.00 to $15.00 and gave the stock an “outperform” rating in a report on Thursday, July 20th. Ifs Securities reaffirmed a “strong-buy” rating on shares of CymaBay Therapeutics in a report on Monday, July 17th. Finally, CIBC reaffirmed an “outperform” rating and set a $15.00 target price (up from $8.00) on shares of CymaBay Therapeutics in a report on Thursday, July 20th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $12.28.
TRADEMARK VIOLATION NOTICE: “CymaBay Therapeutics (CBAY) Earns Daily News Impact Score of 0.06” was published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/cymabay-therapeutics-cbay-earns-daily-news-impact-score-of-0-06/1535156.html.
In related news, insider Sujal Shah bought 10,000 shares of the stock in a transaction on Thursday, July 20th. The shares were purchased at an average price of $7.34 per share, for a total transaction of $73,400.00. Following the acquisition, the insider now owns 75,891 shares in the company, valued at $557,039.94. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert James Wills bought 5,000 shares of the stock in a transaction on Tuesday, August 1st. The shares were bought at an average price of $6.84 per share, for a total transaction of $34,200.00. Following the acquisition, the director now owns 25,200 shares in the company, valued at approximately $172,368. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 20,000 shares of company stock worth $144,750. Insiders own 15.10% of the company’s stock.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.